Erin Xie

Erin Xie is a Managing Director at BlackRock and heads the Health Sciences team within BlackRock Fundamental Equities. BlackRock describes her as the lead portfolio manager for its Health Sciences equity portfolios. Her tenure with the firm dates to 2001, including her years at State Street Research & Management, which merged with BlackRock in 2005.

At State Street Research & Management, Xie was a Senior Vice President and portfolio manager responsible for the State Street Health Sciences Fund. Before joining State Street Research in 2001, she worked as a research associate at Sanford Bernstein covering the pharmaceutical industry, with some fund biographies specifying that role from 1999.

Xie’s pre-investing background is scientific. From 1994 to 1997, she was a post-doctoral research scientist at Columbia University. She earned a BS in chemistry from Beijing University in 1988, a PhD in biochemistry from UCLA in 1993, and an MBA from MIT Sloan in 1999.

Her current portfolio-management work is centered on healthcare-sector public equities. BlackRock’s Health Sciences Opportunities Fund lists the strategy as investing at least 80% of total assets in securities of companies in health sciences and related industries, and BlackRock highlights “investment expertise enhanced by scientific experience” as part of the fund’s positioning.

• Focuses on healthcare and health-sciences public equities rather than seed-stage venture investing; I found no verified evidence that she writes seed checks.
• BlackRock’s stated strategy for the Health Sciences Opportunities Fund is to invest at least 80% of assets in companies in health sciences and related industries, including non-U.S. companies where appropriate.
• Xie and Carrie King argued in a May 15, 2026 BlackRock article that healthcare offers innovation exposure beyond technology, with lower correlation to tech and defensive characteristics from recurring medical demand.
• They specifically highlighted AI’s healthcare use cases in diagnostics, imaging, pathology, clinical decision support, research productivity, genomic datasets, and more personalized cancer detection and treatment.
• Their 2026 view emphasized active management because healthcare outcomes vary widely by subsector, with return dispersion driven by innovation, regulatory developments, and company-specific fundamentals.
• The thesis appears to favor differentiated, research-intensive stock selection in healthcare companies where scientific, regulatory, demographic, valuation, and earnings fundamentals are mispriced.